Top Consumer Driven Health Care Stories
Novo Nordisk to significantly reduce U.S. list price for GLP-1s beginning in 2027
By Michael PopkeThe price drop builds on concerted efforts by Novo Nordisk to improve patient access, particularly to weight-loss drugs Wegovy and Ozempic, according to company officials.



